Skip to content
10-Q

Quarterly Report

CNS Pharmaceuticals, Inc. CNSP

0001683168-26-003847

← back to feed
Filed
May 14, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2026 · May 13, 2026 1.46M sh
Shares Diluted Q1 2026 · Mar 31, 2026 676.17K sh
Shares Diluted restated Q1 2026 · Mar 31, 2025 227.22K sh
Capex Q1 2026 · Mar 31, 2026 $6.18K
Capex Q1 2026 · Mar 31, 2025 $0
Operating Cash Flow Q1 2026 · Mar 31, 2026 −$4.65M
Operating Cash Flow Q1 2026 · Mar 31, 2025 −$3.24M
Cash And Equivalents Q1 2026 · Mar 31, 2026 $2.95M
Cash And Equivalents Q1 2026 · Dec 31, 2025 $7.2M
Stockholders Equity Q1 2026 · Mar 31, 2026 $70.71K
Stockholders Equity Q1 2026 · Dec 31, 2025 $4.52M
Stockholders Equity Q1 2026 · Mar 31, 2025 $10.97M
Stockholders Equity Q1 2026 · Dec 31, 2024 $6.18M
Current Liabilities Q1 2026 · Mar 31, 2026 $4.58M
Current Liabilities Q1 2026 · Dec 31, 2025 $4.1M
Total Liabilities Q1 2026 · Mar 31, 2026 $4.58M
Total Liabilities Q1 2026 · Dec 31, 2025 $4.1M
Current Assets Q1 2026 · Mar 31, 2026 $4.08M
Current Assets Q1 2026 · Dec 31, 2025 $8.1M
Total Assets Q1 2026 · Mar 31, 2026 $4.65M
Total Assets Q1 2026 · Dec 31, 2025 $8.62M
Eps Diluted Q1 2026 · Mar 31, 2026 −$7.30
Eps Diluted restated Q1 2026 · Mar 31, 2025 −$18.93
Eps Basic Q1 2026 · Mar 31, 2026 −$7.30
Eps Basic restated Q1 2026 · Mar 31, 2025 −$18.93
Sga Expense Q1 2026 · Mar 31, 2026 $1.43M
Sga Expense Q1 2026 · Mar 31, 2025 $1.09M
Rd Expense Q1 2026 · Mar 31, 2026 $3.54M
Rd Expense Q1 2026 · Mar 31, 2025 $3.24M
Net Income Q1 2026 · Mar 31, 2026 −$4.94M
Net Income Q1 2026 · Mar 31, 2025 −$4.3M
Operating Income Q1 2026 · Mar 31, 2026 −$4.98M
Operating Income Q1 2026 · Mar 31, 2025 −$4.34M